, Tracking Stock Market Picks
Enter Symbol:
Ym Biosciences, Inc. (YMI) [hlAlert]

Mkt Outperform
up 17.60 %

Ym Biosciences, Inc. (YMI) rated Mkt Outperform with price target $5 by JMP Securities

Posted on: Tuesday,  Mar 15, 2011  10:25 AM ET by JMP Securities

JMP Securities rated Mkt Outperform Ym Biosciences, Inc. (AMEX: YMI) on 03/15/2011, when the stock price was $2.50.
Since then, Ym Biosciences, Inc. has gained 17.60% as of 02/08/2013's recent price of $2.94.
If you would have followed this JMP Securities's recommendation on YMI, you would have gained 17.6% of your investment in 696 days.

YM BioSciences Inc. is a biopharmaceutical company engaged in the development of products primarily for the treatment of patients with cancer. The Company owns or in-license substances or products in order to advance them along the regulatory and clinical pathways toward commercial approval. The Company?s portfolio of products in active clinical development includes one anti-cancer agent (a monoclonal antibody) in a number of clinical trials targeting more than 10 different tumors and/or stages of cancer, and an inhalation-delivery approach for fentanyl to treat acute pain, including cancer pain. The Company?s two product candidates in the clinical stage of development, as of June 30, 2009, were NIMOTUZUMAB and AeroLEF. Its three additional products licensed that are not in clinical development include Tesmilifene and two anti-cancer vaccines, a TGFα vaccine and a HER1-targeting vaccine.

MP Securities' equity research department provides institutional clients with comprehensive industry knowledge, unique insight and actionable information. JMP's senior research analysts are charged with developing proprietary investment themes, anticipating secular and cyclical changes and producing action-oriented reports. JMP follows companies in six industries that exhibit above-average long-term growth characteristics — Technology, Healthcare, Consumer, Real Estate, Financial Services and Business Services — and produces specialized equity research that enables investors to understand and invest in complicated growth stocks profitably.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/15/2011 10:25 AM Buy
2.50 5.00
as of 12/30/2011
1 Week up  7.18 %
1 Month up  29.13 %
3 Months down  -11.82 %
1 YTD down  -34.40 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy